By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Life Technologies said today that its board has authorized the repurchase of up to $500 million in shares.

The program authorizes the company's management to repurchase shares on the open market or in privately negotiated transactions.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.